GBS Inc. (GBS)
After hours:
| Previous close | 0.3944 |
| Open | 0.4200 |
| Bid | 0.4200 x 2200 |
| Ask | 0.4273 x 900 |
| Day's range | 0.4200 - 0.4400 |
| 52-week range | 0.3600 - 2.8900 |
| Volume | |
| Avg. volume | 50,617 |
| Market cap | 6.254M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5020 |
| Earnings date | 11 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.50 |
- GlobeNewswire
GBS Inc. Reports Fourth Quarter and Full Year ended June 30, 2022 Preliminary Financial Results and Recent Business Highlights
- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition - - Completed collection and analysis in a study with coincidental sampling of oral fluid and blood to evaluate the time-course of glucose in oral fluids - - Company to host conference call & webcast today at 4:30 p.m. ET - NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasi
- GlobeNewswire
GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31
Company to Host Conference Call & Webcast at 4:30 p.m. ETNEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the fourth quarter and full year ended June 30, 2022, shortly after the NASDAQ market close on Wednesday, August 31. Management will then host a conference call and
- GlobeNewswire
GBS Inc. Announces Key Milestone in Prospective Study Comparing Glucose in Oral Fluids and Blood
The trial is single center, prospective study collecting coincident samples of oral fluids and blood to evaluate the time-course of glucose NEW YORK, July 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced completion of sample collection and analysis of glucose in oral fluid and blood samples from their clinical study at the Diabete
